Retirement Systems of Alabama Sells 1,761 Shares of Moderna, Inc. (NASDAQ:MRNA)

Retirement Systems of Alabama lowered its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 2.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 73,107 shares of the company’s stock after selling 1,761 shares during the period. Retirement Systems of Alabama’s holdings in Moderna were worth $7,270,000 as of its most recent filing with the SEC.

A number of other large investors also recently added to or reduced their stakes in MRNA. Arlington Trust Co LLC increased its holdings in shares of Moderna by 4,833.3% in the fourth quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock worth $29,000 after buying an additional 290 shares during the period. GPS Wealth Strategies Group LLC increased its stake in Moderna by 54.1% in the 3rd quarter. GPS Wealth Strategies Group LLC now owns 513 shares of the company’s stock worth $53,000 after purchasing an additional 180 shares during the period. Archer Investment Corp lifted its position in Moderna by 71.2% in the third quarter. Archer Investment Corp now owns 534 shares of the company’s stock valued at $55,000 after purchasing an additional 222 shares during the last quarter. Parkside Financial Bank & Trust boosted its stake in shares of Moderna by 44.9% during the third quarter. Parkside Financial Bank & Trust now owns 565 shares of the company’s stock valued at $58,000 after purchasing an additional 175 shares during the period. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA grew its holdings in shares of Moderna by 408.3% in the third quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 610 shares of the company’s stock worth $63,000 after purchasing an additional 490 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Stock Performance

Shares of MRNA stock opened at $125.00 on Friday. The company’s fifty day moving average price is $105.05 and its 200-day moving average price is $94.42. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.36 and a current ratio of 4.03. Moderna, Inc. has a 12 month low of $62.55 and a 12 month high of $142.79.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, May 2nd. The company reported ($3.07) EPS for the quarter, topping the consensus estimate of ($3.59) by $0.52. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The business had revenue of $167.00 million for the quarter, compared to analyst estimates of $93.26 million. During the same quarter in the previous year, the firm posted $0.19 earnings per share. Moderna’s quarterly revenue was down 91.0% on a year-over-year basis. Equities analysts expect that Moderna, Inc. will post -7.47 earnings per share for the current year.

Insider Transactions at Moderna

In related news, CFO James M. Mock sold 647 shares of the firm’s stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $61,186.79. Following the completion of the transaction, the chief financial officer now owns 4,300 shares of the company’s stock, valued at approximately $406,651. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $110.92, for a total value of $1,663,800.00. Following the transaction, the director now owns 2,026,931 shares in the company, valued at $224,827,186.52. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO James M. Mock sold 647 shares of the firm’s stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total transaction of $61,186.79. Following the sale, the chief financial officer now directly owns 4,300 shares of the company’s stock, valued at approximately $406,651. The disclosure for this sale can be found here. Insiders have sold a total of 139,954 shares of company stock valued at $14,822,576 in the last ninety days. 15.70% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. William Blair reiterated a “market perform” rating on shares of Moderna in a report on Monday, April 1st. Canaccord Genuity Group increased their target price on shares of Moderna from $91.00 to $106.00 and gave the stock a “hold” rating in a report on Friday. Royal Bank of Canada boosted their price target on Moderna from $125.00 to $135.00 and gave the company an “outperform” rating in a report on Friday. Oppenheimer increased their price objective on Moderna from $142.00 to $163.00 and gave the stock an “outperform” rating in a report on Friday. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research report on Thursday. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $129.55.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.